Trial Profile
A Safety Lead-In/Randomized Phase 2 Study of BMX-001 as a Therapeutic Agent for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs BMX 001 (Primary)
- Indications Brain metastases
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioMimetix
- 17 Apr 2024 Status changed from recruiting to discontinued.
- 15 Feb 2023 Planned End Date changed from 30 Sep 2024 to 30 Sep 2025.
- 15 Feb 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Aug 2024.